Skip to content
Evigrade
CriticalReversible MAO-A inhibitor (RIMA)×Selective serotonin reuptake inhibitors (SSRIs)

Updated · Methodology

Mechanism

Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, section 5.1). Sertraline is a potent and selective inhibitor of neuronal serotonin reuptake (sertraline SmPC, section 5.1). Because of the risk of serotonin syndrome, the Spanish sertraline SmPC lists reversible selective MAO inhibitors such as moclobemide among contraindicated drugs (section 4.5). In the liver, several pathways break down sertraline, including the cytochrome P450 (CYP) enzymes CYP3A4, CYP2C19 and CYP2B6 (sertraline SmPC, section 5.2). Moclobemide inhibits CYP2C19, so the moclobemide SmPC calls for care with drugs that this enzyme metabolises (moclobemide SmPC, section 4.5). The SmPCs do not say how much moclobemide changes sertraline concentrations. In poor CYP2C19 metabolisers, sertraline levels are about 50% higher, with unclear clinical relevance (sertraline SmPC, section 5.2). Sertraline is a mild to moderate CYP2D6 inhibitor, and CYP2D6 partly takes part in moclobemide metabolism, but moclobemide has alternative pathways, and such effects generally do not call for a dose change (sertraline SmPC, section 4.5, and moclobemide SmPC, section 5.2).

Symptoms

When sertraline is combined with monoamine oxidase (MAO) inhibitors, serotonin syndrome may present with agitation, tremor and high temperature (sertraline summary of product characteristics, SmPC, section 4.3). Severe reactions have been reported when an MAO inhibitor was stopped shortly before sertraline was started, or sertraline was stopped shortly before an MAO inhibitor. They included tremor, muscle jerks (myoclonus), heavy sweating, nausea, vomiting, flushing, dizziness, high temperature with features resembling neuroleptic malignant syndrome, seizures and death (sertraline SmPC, section 4.5). When moclobemide was combined with other antidepressants, including sertraline, isolated cases of a severe combination of high temperature, confusion, overactive reflexes (hyperreflexia) and myoclonus occurred (moclobemide SmPC, section 4.5). According to the US Food and Drug Administration (FDA) sertraline label, serotonin syndrome may also include hallucinations, delirium, coma, fast heart rate, labile blood pressure, flushing, muscle rigidity, poor coordination and diarrhoea (section 5.2).

Management

The combination is contraindicated. The Spanish sertraline summary of product characteristics (SmPC) lists reversible selective monoamine oxidase (MAO) type A inhibitors such as moclobemide among contraindicated drugs (section 4.5). The US Food and Drug Administration (FDA) sertraline label contraindicates any MAO inhibitor and use within 14 days of stopping one (sections 4 and 7.1). The moclobemide SmPC is less strict and advises caution when sertraline and other antidepressants that raise serotonin are given with moclobemide (section 4.5). According to the Spanish SmPCs, the washout after a reversible MAO inhibitor may be shorter than 14 days before sertraline (sertraline SmPC, section 4.5), and another antidepressant can be started the day after moclobemide is stopped (moclobemide SmPC, section 4.5). Stop sertraline at least 7 days before starting a reversible MAO inhibitor (sertraline SmPC, section 4.5). When switching to moclobemide, take the half-life of sertraline into account (moclobemide SmPC, section 4.5): about 26 hours, and 62–104 hours for its main metabolite (sertraline SmPC, section 5.2). The FDA sertraline label sets longer intervals: at least 14 days between an MAO inhibitor antidepressant and sertraline, in either direction (sections 2.5 and 4). If the two drugs have nevertheless been taken together, monitor the patient for signs of serotonin syndrome or neuroleptic malignant syndrome (sertraline SmPC, section 4.4). If signs of serotonin syndrome appear, stop sertraline and other serotonergic drugs immediately and start supportive symptomatic treatment (FDA sertraline label, section 5.2). The moclobemide SmPC advises considering a lower moclobemide dose or stopping it, depending on how severe the symptoms are (section 4.4). If high temperature, confusion, hyperreflexia and myoclonus occur together, keep the patient under medical observation, in hospital if needed (moclobemide SmPC, section 4.5).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Moclobemide

Other interactions with Sertraline